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Tbjectives: Cellular cardiomyoplasty using skeletal myoblasts or angiopoietic pro-
enitor cells offers a promising approach for the treatment of ischemic heart failure.
lthough several studies have shown encouraging results in acute myocardial
nfarction, the efficacy of cell therapy using skeletal myoblasts and angiopoietic
rogenitor cells in chronic ischemic heart disease remains undetermined.
ethods: Ischemic heart failure was induced by left anterior descending coronary
rtery ligation in nude rats: (1) Culture medium, (2) homologous skeletal myoblasts
SM), (3) human AC-133 cells (SC), and (4) both skeletal myoblasts and AC-
33 cells (Comb) were injected in the infarct (SM) and peri-infarct area (SC)
weeks after infarction. Assessment of myocardial function included echocardiog-
aphy 4 weeks after cell delivery. Histology was based on quantification of myo-
ardial fibrosis, apoptosis, and capillary density.
esults: Left ventricular dilatation was attenuated and ejection fraction improved
ignificantly after cell transplantation (SM: 59.4%  8.8%, SC: 60.3%  6.6%,
omb: 68.2% 5.6% vs control: 41.5% 7.4%, P .0013). Quantification of scar
issue showed a significant reduction of infarct area in cell-treated animals (SM:
2.3%  9.1%, SC: 19.8%  7.6%, Comb: 13.2%  5.8% vs controls: 36.5% 
.2%, P  .008). Improvement of myocardial function was associated with reduced
poptotic index (SM: 3.2%  0.9%, SC: 3.1%  0.6%, Comb: 1.8%  0.8% vs
ontrols: 10.3% 1.6%, P .0002) and increased vascular density (SM: 5.2 1.2,
C: 8.3  1.8, Comb: 12.3  2.3, controls: 1.9  0.3, all capillary vessels/high-
ower field, P  .007) in animals after cellular cardiomyoplasty.
onclusions: Combined transplantation of skeletal myoblasts and angiopoietic
rogenitor cells results in ventricular function improvement, reduction of scar size
nd myocardial apoptosis, and increased neoangiogenesis in chronic ischemia.
linical studies are warranted to prove this new therapeutic concept.
keletal myoblast transplantation into the ischemic heart can improve myo-
cardial function with a passive girdling effect by limiting progressive cavity
dilatation.1,2 Recent studies have provided additional information regard
he possible mechanisms and set the pace for preliminary clinical studies.3,4 Those
tudies have shown that skeletal myoblasts possess a substantial angiogenic poten-
ial and are able to partially replace infarcted myocardium and reverse remodeling
rovided that they survive in large numbers in the host.5-7
Several drawbacks have limited the initial optimism of myoblast-based myocar-
ial regeneration. First, although engrafted skeletal myoblasts form beating struc-
he Journal of Thoracic and Cardiovascular Surgery ● Volume 132, Number 6 1321
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CSPures in the infarct scar, they beat asynchronously to native
ardiomyocytes.8 In addition, survival of engrafted cell
ess than 1%, and the average improvement of left ventric-
lar ejection fraction (LVEF) after myoblast transplantation
oes not exceed 8%.3,4,7 Therefore, strategies to improv
iability of the peri-infarct area are required to warrant a
etter environment for the engrafted cells.
Angiopoietic progenitor cells have been shown to im-
rove blood and oxygen supply in the scar. The earliest
recursor of both hematopoietic and endothelial cell lineage
erived from embryonic ventral endothelium expresses vas-
ular endothelial growth factor (VEGF) receptors, as well as
ATA-2, 4-integrins, and the AC133-receptor.9 AC-133
ells possess paracrine properties and have been shown to
nduce angiogenesis by means of angiogenic factors secre-
ion.10 Their ability to transdifferentiate into endothel
ells with high proliferation capacity is associated with new
essel formation mainly attributed to vasculogenesis.11 Al-
hough AC-133 cells do express early cardiac markers12
heir potential to transdifferentiate into functional cardio-
yocytes has been questioned.13
In the current study we evaluated the efficacy of a
ombined transplantation of (1) AC-133 progenitors for
nduction of angiogenesis in the still viable border zone and
2) skeletal myoblasts for replacement of lost contractile
tructures in the infarct scar in a rodent model of chronic
schemic heart failure.
ethods
odel of Myocardial Infarction and Ischemic
eart Failure
yocardial infarction was induced in 8- to 10-week-old male
nu/rnu rats (Harlan Winkelmann, Borchen, Germany) through left
nterior descending coronary artery ligation. All animals received
umane care in compliance with the “Principles of Laboratory
nimal Care,” formulated by the National Society for Medical
esearch, and the “Guide for the Care and Use of Laboratory
nimals,” prepared by the Institute of Laboratory Animal Re-
ource and published by the National Institutes of Health.
solation, Labeling, and Culture of Skeletal Myoblasts
rom Syngeneic Rats
at skeletal myoblasts were isolated from 6-week-old male F344
Abbreviations and Acronyms
LVEDD left ventricular end-diastolic diameter
LVEF  left ventricular ejection fraction
TUNEL  deoxyuride-5=-triphosphate biotin nick end
labeling
VEGF  vascular endothelial growth factor
YFP  yellow fluorescent proteinats (syngeneic rats). Isolation, culture, and expansion procedures p
322 The Journal of Thoracic and Cardiovascular Surgery ● Decave been described.14 Stable transgenic rat skeletal myoblas
ere generated by a plasmid encoding for the yellow fluorescent
rotein (YFP) (Invitrogen Corporation, Vienna, Austria) contain-
ng the neomycin resistance gene for subsequent selection of stable
FP clones. Purity of clonal myoblast cultures was proved by
eans of desmin immunohistology (IMMH-5, Sigma, St Louis,
o) and antiskeletal myosin-fast antibodies (clone My-32,
igma). All sections were overlaid to pictures obtained by fluo-
escence microscopy and were double-confirmed with myosin
eavy chain fast-slow staining (clone My-32, Sigma) to confirm
ell tracking.
solation, Purification, and Labeling of Human-derived
C-133 Angiopoietic Progenitors
ononuclear cells were obtained from single-donor leukapheresis
roducts of individuals mobilized with recombinant granulocyte
olony-stimulating factor 10 g/kg subcutaneously (Neupogen,
mgen, Thousand Oaks, Calif) for at least 4 days. Highly purified
D133 cells (98% positive) were obtained within 48 hours after
lood collection using magnetic beads coated with monoclonal anti-
odies against CD133 (Miltenyi Biotech, Bergisch-Gladbach, Ger-
any). Cell purity was controlled by means of flow cytometry
sing antibodies against CD45 and CD133 (Becton Dickinson,
ranklin Lakes, NJ). AC-133 cells were cultured with 10 g/mL
ipoprotein labeled with carbocyanine membrane 1,1-dioctadecyl-
,3,3,3-tetramethyl indocarbocyanine perchlorate (Cell-Tracker
M-DiI, Molecular Probes, Leiden, The Netherlands) for subse-
uent cell tracking. After cell viability assessment (propidium
odide staining), aliquots of 106 AC-133 cells in approximately
00 L of culture medium (Roswell Park Memorial Institute) were
repared for intramyocardial injections. Cell tracking included DiI
uorescence detection using fluorescence microscopy and coun-
erstaining with human-specific anti-human leukocyte antigen
lass I (clone w6/32, Sigma) using immunohistochemistry.
ell Transplantation
our weeks after myocardial infarction and after echocardio-
raphic verification of chronic heart failure, rats were reanesthe-
ized and hearts were reexposed through a left redo-thoracotomy to
llow access to the infarct area and the peri-infarct rim proximally
nd distally to the scar. Roswell Park Memorial Institute culture
edium (n  5), 106 YFP-labeled, desmin-positive skeletal myo-
lasts from syngeneic rats (n  5), 106 DiI-labeled AC-133
uman-derived angiopoietic progenitor cells (n  5), and a com-
ination of 5  105 YFP-labeled, desmin-positive skeletal myo-
lasts from syngeneic rats, and 5  105 DiI-labeled AC-133
uman-derived angiopoietic progenitor cells were injected in the
eri-infarct area and the scar (n  5). Skeletal myoblasts and
C-133 cells were exclusively injected in the infarct scar and the
eri-infarct area, respectively.
unctional Assessment by Transthoracic
chocardiography
ransthoracic echocardiography was performed before and 2 days
fter myocardial infarction, and 4 weeks after cell transplantation
ith an Acuson Sequoia Echocardiography system (Acuson Cor-
oration, Mountain View, Calif), with a commercially available
ember 2006
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P5-MHz linear-array intracardiac transducer system (AcuNav,
cuson Corporation).
nimal Sacrifice and Preparation for
orphologic Studies
ats were euthanatized, hearts were harvested, and fibrous tissues
ere removed. After the intracardiac blood was rinsed, the hearts
ere divided into 3 equally thick parts representing the base, the
iddle, and the apex of the heart. Each of them was snap-frozen in
iquid nitrogen after being embedded in optimal cutting tempera-
ure compound (Tissue-Tec OCT Compound, Miles Inc, Elkhart,
nd). From each part, 5-m slides were prepared using cryostat.
ransplanted cells were detected by confocal fluorescence micros-
opy. In addition, standard hematoxylin-eosin staining was 
ormed to permit morphologic assessment.
valuation of Myocardial Fibrosis and Quantification
f Myocardial Infarction
o assess fibrosis in the left ventricular myocardium, heart samples
ere cut into transverse sections and stained with Masson’s Trichrome
Merck, Darmstadt, Germany). Transverse sections were randomly
btained from the 3 parts described; after staining, they were
canned and computerized for digital image analysis. Fibrotic area
raction was calculated as the sum of the whole fibrotic area
ivided by the total myocardial area. The peri-infarct region or
order zone was defined as the region of myocardium extending at
east 0.5 mm from the infarct scar.
valuation of Capillary Density
o detect capillaries in the myocardium, frozen transverse
ections were randomly obtained from all 3 heart parts and
tained using an anti-CD34 monoclonal antibody (clone QBEnd-
0; DakoCytomation, Glostrup, Denmark). Immunohistochemical
isualization was performed with the EnVision kit (DakoCytoma-
ion). The number of capillaries were counted in the border zone
nd distal area. Capillary density was expressed as the average
umber of capillaries of 5 random high-power fields.
valuation of Apoptotic Index in the Left
entricular Myocardium
or in situ detection of apoptosis at the single-cell level, transferase-
ediated deoxyuride-5=-triphosphate biotin nick end labeling
TUNEL) staining was performed with the In Situ Cell Death
etection Kit/Peroxidase (Roche, Indianapolis, Ind) according to
he instructions of the manufacturer. Within each field, 5 randomly
elected regions of infarct scar, peri-infarct rim, and rest myocar-
ium were examined, containing at least 250 cells per region. The
esults were expressed as the apoptotic index representing the ratio
f apoptotic cells of the total myocardial cell population.
ata Analysis
tatistical analysis was performed with the Statistical Package for
he Social Sciences 11.0 for Windows (SPSS Inc, Chicago, Ill).
ata are expressed as mean  standard deviation. Comparisons of
ontinuous variables among animal groups were studied by 1-way
nalysis of variance. Longitudinal studies comparing data within
ach group were achieved with paired t tests. i
The Journal of Thoracicesults
ransplanted Skeletal Myoblasts and AC-133
ngiopoietic Progenitors Survive in the Environment
f Chronic Ischemia
FP-labeled homologous skeletal myoblasts were detected
n the infarct scar (Figure 1, A). My-32 antibody stainin
evealed stable engraftment of skeletal myoblasts in the
nfarct area but not in the border zone (Figure 1, B). En-
rafted cells formed organized cell aggregates (myotubes)
hat remained morphologically isolated from the host myo-
ardium (Figure 1, C).
In addition, DiI cells representing injected AC-133
ells were detected in cryosections derived from the group
hat received stem-cell injections. Those cells had a com-
letely different pattern of engraftment as they formed
pot-like colonies (Figure 1, D).
In the combination group, both cell types were detected
n chronic ischemic myocardium presenting patterns of en-
raftment similar to those in the single-cell therapy groups
Figure 1, E). AC-133 cells were not only detected in 
order zone but also in the infarct scar, although they were
njected in the peri-infarct rim. This finding indicates that
ematopoietic progenitors not only survive for an extended
eriod of time after transplantation in chronic ischemic
yocardium but also migrate to the infarct scar.
ombined Transplantation of Skeletal Myoblasts and
C-133 Progenitors Reverses Left Ventricular
ilatation and Improves Systolic Heart Function
e assessed left ventricular end– diastolic diameter
LVEDD) as a marker of left ventricular remodeling by
eans of transthoracic echocardiography. LVEDD in-
reased after infarction and was almost doubled compared
ith the baseline diameter in control animals (Figure 2A).
ransplantation of either skeletal myoblasts or angiopoietic
rogenitors resulted in approximately 20% lower levels of
VEDD compared with controls (online Figures E1 
2). Left ventricular dilatation was significantly reduced
nimals, which received both cell types, as LVEDD de-
reased from 0.92 mm in the control group to 0.60 mm in
he combination group.
LVEF significantly decreased from more than 70% to
ess than 40% after induction of myocardial infarction in
ll animals. Akinetic areas were detectable in the anterior
all and apex. In control animals, LVEF remained less than
0% at 4 weeks after injection of culture medium (Figu
). A statistically significant increase of systolic left ven-
ricular function in animals that received cell monotherapy
as observed with a relative improvement of 50% com-
ared with the LVEF levels early after infarction. Animals
ubjected to combined cell therapy had a more profound
ncrease of LVEF, reaching a relative improvement of ap-
roximately 70% compared with baseline. To assess the
mpact of remodeling, LVEDD and LVEF were evaluated in
and Cardiovascular Surgery ● Volume 132, Number 6 1323
1
(
(
o
t
g
d
(
C
A
a
W
e
m
t
t
d
M
m
r
1
p
c
p
t
D
A
Z
T
m
b
i iv-
i
o
s
e
E
m
z s of
Cardiopulmonary Support and Physiology Bonaros et al
1
CSP0 separate experiments 2 days after myocardial infarction
postoperative day 2) and 2 days before cell transplantation
postoperative day 26). No difference was observed in terms
f LVEF (39.3%  4.2% vs 38.2%  3.9%) between the 2
ime points and before assignment to the 4 different therapy
roups. LVEDD was significantly higher on postoperative
ay 26, suggesting postremodeling ventricular dilatation
0.44  0.05 vs 0.64  0.07, P  .02).
ombined Transplantation of Skeletal Myoblasts and
ngiopoietic Progenitors Prevents Myocardial Fibrosis
nd Results in Reduced Myocardial Scar
e next examined whether combined cell therapy had an
ffect on the myocardial scar in the setting of chronic
yocardial ischemia by quantifying the ratio of fibrous
issue to the left ventricle at 4 weeks after cell transplanta-
ion (Figure 3, A, B). A scar area of 36.5%  8.2% was
etected in control animals 4 weeks after medium injection.
asson’s Trichrome staining from animals of the skeletal
yoblast and the stem cell group revealed a significanteduction of myocardial scar to 22.3%  9.1% and a
324 The Journal of Thoracic and Cardiovascular Surgery ● Dec9.8%  7.6%, respectively. This reduction was more
rominent in animals that received transplantation of both
ell types (13.2%  5.8%, P  .036 and P  .044, com-
ared with skeletal myoblasts and AC-133 cells, respec-
ively) (Figure 3, C).
ouble-cell Therapy With Skeletal Myoblasts and
C-133 Cells Attenuates Apoptosis in the Border
one and Distal Area
o evaluate the effect of cell-therapy types on surviving
yocardium, we performed a TUNEL staining of both the
order zone and the distal area and calculated the apoptotic
ndex (Figure 4, A, B). Approximately two thirds of surv
ng cardiomyocytes were apoptotic in the peri-infarct area
f control animals, whereas the extent of apoptosis was
ignificantly lower after single-cell transplantation of skel-
tal myoblasts or AC-133 cells (online Figures E3 and E4).
quivalent sections from the combination group revealed an even
ore profound attenuation of myocardial apoptosis in the border
one (Figure 4, C). Similar results were obtained after analysi
Figure 1. Transplanted skeletal myo-
blasts and AC-133 angiopoietic pro-
genitors survive in chronic ischemic
myocardium. A, Fluorescent staining of
YFP-labeled skeletal myoblasts (green)
in the infarct area detected 4 weeks
after cell injection (40 magnifica-
tion). B, Immunohistochemical staining
of skeletal myoblasts by My-32 anti-
body confirms fluorescence-based cell
detection in the infarct scar (40 mag-
nification). C, Immunofluorescent stain-
ing of My-32 (red) showing stable myo-
tube formation in the scar (cell nuclei
stained blue) (100 magnification). D,
Fluorescent staining of DiI-labeled AC-
133 cells (red) in the border zone 4
weeks after cell transplantation (40
magnification). E, Fluorescent staining
of skeletal myoblasts (green) and AC-
133 cells (red) in the infarct area 4
weeks after combined cell transplan-
tation of skeletal myoblasts and AC-
133 cells in the scar and border zone,
respectively (100 magnification).poptotic rates in the remote area, indicating that the beneficial
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Pffect of double-cell therapy is not limited to the immediate
schemic tissue (Figure 4, D). To investigate the effect of co
ined cell therapy on the newly formed myotubes, we assessed
poptotic rates within engrafted skeletal myoblasts in the infarct
car. The apoptotic index was significantly lower in animals that
eceived double-cell therapy (0.42  0.19) compared with ani-
als that received homologous skeletal myoblasts alone (0.79
.15, P  .0004).The Journal of Thoracicombined Transplantation of Skeletal Myoblasts and
ngiopoietic Progenitors Increases Capillary Density
n Chronic Ischemic Myocardium
ecause both cells have been shown to increase neoangio-
enesis in the ischemic heart, we next studied the effects of
ombined cell transplantation on capillary density in chronic
schemic myocardium (Figure 5, A, B). Capillary density in t
order zone and scar area was significantly higher in rats after
Figure 2. Combined transplantation of
skeletal myoblasts and AC-133 progeni-
tors reverses left ventricular dilatation (A)
and improves left ventricular function (B),
as assessed by transthoracic echocardiog-
raphy 4 weeks after cell transplantation
(results expressed as mean standard de-
viation). M-Mode echocardiography, i., 2
days after myocardial infarction; ii., 4
weeks after double-cell therapy. Animals
received Roswell Park Memorial Institute
injections in the scar and peri-infarct rim
(control), homologous skeletal myoblasts in
the scar (SM), human-derived AC-133
cells in the peri-infarct rim (SC), homolo-
gous skeletal myoblasts and human-
derived AC-133 cells (Comb) in the scar
and peri-infarct rim, respectively. Note an-
terior wall hypokinesia and left ventricular
dilatation after myocardial infarction (ar-
row). Both findings are partially reversed 4
weeks after combined cell therapy (arrow).
Figure 3. Combined transplantation of
skeletal myoblasts and angiopoietic
progenitors prevents myocardial fibro-
sis and results in reduced myocardial
scar, as assessed by Masson’s
Trichrome staining 8 weeks after myo-
cardial infarction. A, Scar area of a
control animal 4 weeks after injection
of culture medium (40 magnification).
B, Scar area of an animal after myocar-
dial infarction and 4 weeks after skeletal
myoblasts transplantation (40 magnifi-
cation). C, Quantification of myocardial
fibrosis 4 weeks after injection of culture
medium (control), homologous skeletal
myoblasts (SM), human-derived AC-133
cells (SC), or combination of homologous
skeletal myoblasts and human-derived
AC-133 cells.and Cardiovascular Surgery ● Volume 132, Number 6 1325
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CSPell monotherapy compared with controls, with a trend of more
apillaries in the group receiving AC-133 cells than the
roup receiving skeletal myoblasts (online Figures E5 and 
ombined transplantation of skeletal myoblasts and AC-133
ells resulted in a 6.5- and 1.6-fold increase of capillary density
ompared with controls and skeletal myoblast monotherapy,
espectively (Figure 5, C). Similar results were observed w
egard to the capillary density in the infarct area (Figure D).326 The Journal of Thoracic and Cardiovascular Surgery ● Deciscussion
n the current study we evaluated the effect of combined
ransplantation of skeletal myoblasts in the infarct area and
ngiopoietic progenitor cells in the border zone in a rodent
odel of ischemic heart failure. Although this approach has
een described,14,15 this is the first study to introduce 
oncept of double-cell therapy in an environment of chronic
yocardial ischemia. Other approaches included injections
Figure 4. Double-cell therapy with
skeletal myoblasts and AC-133
cells attenuates apoptosis in the bor-
der zone and distal area, as assessed
by TUNEL staining. TUNEL staining of
the border zone 4 weeks after injec-
tions of (A) culture medium and (B) com-
bination of homologous skeletal myo-
blasts and human-derived AC-133 cells
(brown and blue nuclei indicating apo-
ptotic and non-apoptotic cells, respec-
tively). Quantification of apoptotic index,
calculated as the ratio of apoptotic car-
diomyocytes in the total myocardial cell
population in the border zone (C) and
distal area (D). Results are expressed as
mean  standard deviation.
Figure 5. Degree of neovascularization
in the peri-infarct area of chronic in-
farcted myocardium after injection of
(A) culture medium and (B) combination
of skeletal myoblasts and AC-133 cells.
Quantification of capillary density in the
border zone (C) and scar (D) 4 weeks
after cell transplantation.ember 2006
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Pf modulated skeletal myoblasts with genetically enhanced
rowth factor secretion.16 In a previous study we hypoth-
ized that skeletal myoblasts may attenuate the effect of
hronic myocardial ischemia, provided that blood and oxy-
en supply from the peri-infarct area are not restricted.14 In
he present study we selected a specific subgroup of endo-
helial progenitor cells that represent only 1% of the cells in
hole bone marrow aspirates or whole blood from granu-
ocyte colony-stimulating factor–mobilized patients17 and
hat have been shown to actively participate in new vessel
ormation.18 In this context, we injected AC-133 angio-
oietic progenitors in the peri-infarct area to increase neo-
ascularization and to subsequently improve blood and
xygen supply in the ischemic myocardium.
We used in vivo and ex vivo studies to show the func-
ional and morphologic effects of combined cell transplan-
ation. Echocardiography studies revealed an impressive
ecovery of approximately 30% in LVEF in the combination
roup. This improvement was significantly higher than that
eported by other authors,14,15 even 4 weeks post-myocardi
nfarction, after establishment of chronic heart failure and
ompletion of the remodeling process. In this setting, myo-
ardial apoptotic rates have been shown to be more than 3
imes higher compared with those after acute myocardial
nfarction, whereas the regeneration capacity of native myo-
ardium remains extremely low.19 Left ventricular dilata-
ion after myocardial infarction, being the main remodeling
arameter, was significantly reduced by using this therapeu-
ic concept. This finding was also described in a model of
emi-chronic ischemia, in which cell injections were per-
ormed 2 weeks after myocardial infarction and actually
efore completion of the remodeling process.15
Functional improvement correlated to histologic findings
f myocardial fibrosis and apoptotic rates in the peri-infarct
egion and distal area. As proposed by other investigators,
keletal myoblasts can partially replace the myocardial scar,
rovided that they survive in sufficient numbers in the h5
hether the reduction of myocardial scar detected in ani-
als that received AC-133 cells is attributed to the for-
ation of new cardiomyocytes, fusions, or limited scar expan-
ion during remodeling remains to be investigated. Lower
poptotic rates in the peri-infarct region in stem cell-treated
nimals, in combination with the fact that no new myocytes
ere detected in the middle of the scar (data not shown),
rovide evidence that factors other than direct myocardial
egeneration are involved.
The major finding of the study was that injections of
ngiopoietic progenitors in the border zone and skeletal
yoblasts in the infarct scar resulted in a significantly
igher neovascularization of the chronic ischemic myocar-
ium. Several studies have underlined the angiogenic effect
f AC-133 cells, which is mainly attributed to expression
f growth factors, such as basic fibroblast growth factor, m
The Journal of ThoracicEGF, and angiopoietin-1.12,20 Secretion of those factor
as been shown to regulate the differentiation of mononu-
lear cells into endothelial cell lineage.21 Skeletal myo-
lasts, although lineage restricted, also demonstrate a
ignificant angiogenic potential, which has been mainly
ttributed to only partially investigated paracrine proper-
ies22 and to increased production of VEGF.6 This hypoth-
sis was also verified by our findings, because increased
ascularization was detected not only in the infarct scar,
here myoblasts were actually injected, but also in the
eri-infarct region.
Angiopoietic progenitor cells were detected in the area of
njection (border zone) and the infarct scar. This demon-
trates that injected cells not only survive in the ischemic
eart but also migrate into the infarct area. Accordingly,
ther investigators were able to detect angiopoietic progen-
tors 4 weeks after cell transplantation in the scar with
olymerase chain reaction, but not with fluorescence mi-
roscopy.23 We believe these differences can be attribu
o the different protocols used or to fluorescence weakening
aused by fusions between engrafted AC-133 cells and
he few residual in-scar cardiomyocytes.24 The higher vas-
ular density detected in the infarct area of animals sub-
ected to double-cell therapy, compared with those receiv-
ng AC-133 cells alone, indicates the presence of an
dditional mechanism of neoangiogenesis. Inflammation
ediators, such as tumor necrosis factor-, interleukin-8, or
tromal cell-derived factor 1, are less likely to stem from
schemic myocardium, because cytokine production and
xpression of chemoattractants decline within days after
yocardial infarction.25 Molecular signals are not expect
o be produced within the infarct area, because the number
f residual cells remains low 4 weeks after infarction, and
hose cells express high apoptotic rates and subsequently
annot be functional. In this context it is unknown whether
hemoattractants secreted from engrafted myoblasts are po-
ent enough to induce migration and homing of AC-133
ells into the scar.26 The fact that injected angiopoiet
rogenitors were detected in the scar only in rats that
eceived double-cell therapy provides us with evidence that
n interaction between the 2 cell types is present that results
n enhanced migration of angiopoietic progenitors into the
car. Both the origin of the chemoattracting mechanisms
nd the potential myoblast-derived intercellular signaling
hould be addressed in future investigations.
The third interesting finding was the effect of combined
ell therapy on the apoptosis rate of skeletal myoblasts.
lthough survival studies of the engrafted cells were not the
im of this study, we hypothesized that the functional ben-
fit of this therapeutic concept was mainly attributed to a
igher oxygen supply for the transplanted myoblasts, which
ay have warranted functional improvement. Engrafted
yotubes, detected more than 1 month after myoblast trans-
and Cardiovascular Surgery ● Volume 132, Number 6 1327
p
t
m
f
d
b
r
w
c
i
t
i
t
f
t
r
n
A
a
i
t
i
t
m
p
e
o
p
c
p
e
m
t
e
r
a
h
p
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
Cardiopulmonary Support and Physiology Bonaros et al
1
CSPlantation, presented high apoptotic rates, showing that al-
hough these cells are believed to be ischemia-resistant, they
ay possess a higher functionality potential, which is there-
ore limited mainly because of apoptotic mechanisms. Ad-
itional injections of angiopoietic progenitor cells in the
order zone resulted in significantly decreased apoptotic
ates of engrafted myotubes. This finding, in combination
ith the fact that vascular density was significantly in-
reased in those animals, provides evidence that functional
mprovement after double-cell therapy is mainly attributed to
he improvement of blood supply for the engrafted myoblasts
n the hostile environment of the scar.
The complexity of the study setting and the high mor-
ality rates of infectious prone nude rats with chronic heart
ailure did not allow a dose-escalation analysis to specify
he ideal dose required or elaborated investigation of ar-
hythmias. For this reason, we injected commonly accepted
umbers of skeletal myoblasts and angiopoietic progenitors.
nother limitation of this study is the absence of survival
nalysis, because this could not performed in a reliable way
n the current study setting. A direct comparison of both cell
ypes in terms of functional and morphologic improvement
n ischemic heart failure has been addressed by other inves-
igators23 and exceeded the purpose of this study.
We conclude that combined transplantation of skeletal
yoblasts and AC-133 angiopoietic progenitor cells im-
roves heart function, partially reverses myocardial remod-
ling, and reduces apoptosis and scar formation in a model
f chronic myocardial infarction. This functional and mor-
hologic improvement is mainly associated with the in-
reased neovascularization. Although both cell types seem to
lay different roles in cardiac regeneration and neoangiogen-
sis, the presence of cellular interactions at the molecular level
ay be responsible for the enhanced efficacy of combination
herapy. However, the exact mechanism of action and the
xtent to which both cell types communicate with each other
emain to be investigated. Testing of this concept in large
nimal models may be useful to address logistic issues such as
arvesting of both homologous skeletal myoblasts and angio-
oietic progenitors before organizing clinical trials.
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CS
PFigures E1 and E2. M-Mode echocardiography before myocardial infarction (E1) and 4 weeks after cell mono-
therapy (E2). Note anterior wall movement and normal dimensions of the left ventricle before myocardial infarction
(arrow, Figure E1) and 4 weeks after cell monotherapy (arrow, Figure E2).
Figures E3 and E4. Double-cell therapy with skeletal myoblasts and AC-133 cells attenuates apoptosis in the
border zone and distal area, as assessed by TUNEL staining. TUNEL staining of the border zone 4 weeks after
injections of homologous skeletal myoblasts (E3) and human-derived AC-133 cells (E4) (brown and blue nuclei
indicating apoptotic and non-apoptotic cells, respectively).
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CSPFigures E5 and E6. Degree of neovascularization in the peri-infarct area of chronic infarcted myocardium after
injection of skeletal myoblasts (E5) and AC-133 cells (E6) as assessed by means of CD34 staining of endothelial
cells.328.e2 The Journal of Thoracic and Cardiovascular Surgery ● December 2006
